Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)

Sanofi/formerly Provention’s Tzield (teplizumab), a CD3 mAb, is the only FDA-approved disease-modifying therapy that delays progression of Stage 2 T1D in patients 8 years and older. However, less than half of U.S. clinicians are impressed with the drug’s ability to delay T1D onset,…